SCHEMBL4360288

SCHEMBL4360288

CS(=O)(=O)O.[Pt]

nearest known ligand 0.00

Known targets — ChEMBL curated mechanism

ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol

The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL128169 0.94
SCHEMBL246838 0.94 CA2 (0.58)
SCHEMBL8596055 0.94 CA2 (0.58)
SCHEMBL105 0.94
SCHEMBL15109974 0.94
SCHEMBL25599 0.94 CA2 (0.58)
SCHEMBL579101 0.89
SCHEMBL22749161 0.89
SCHEMBL429367 0.89
SCHEMBL20570964 0.89

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104768962-B Leaving group is the platinum-like compounds of the malonate derivative containing amino or alkylamino 北京市丰硕维康技术开发有限责任公司 2017-04-05 CN claimed
CN-103703011-B Platinum compounds with leaving group of hydroxy acid derivative containing amino or alkylamino, and preparation method and application thereof 北京市丰硕维康技术开发有限责任公司 2016-06-22 CN claimed
US-11013730-B1 Composition comprising selenazol or thiazalone derivatives and silver and method of treatment therewith THIOREDOXIN SYSTEMS AB (SE) 2021-05-25 US disclosed
US-10058542-B1 Composition comprising selenazol or thiazolone derivatives and silver and method of treatment therewith THIOREDOXIN SYSTEMS AB (SE) 2018-08-28 US disclosed
EP-2740738-B1 PLATINUM COMPOUNDS FOR TREATING CELL PROLIFERATIVE DISEASE, PREPARATION METHODS AND USES THEREOF BEIJING FSWELCOME TECH DEVELOPMENT CO LTD (CN) 2018-03-28 EP disclosed
CN-104995201-B Platinum (II) compound for treating tumor cell proliferative diseases 北京市丰硕维康技术开发有限责任公司 2017-12-22 CN disclosed
CN-104768962-B Leaving group is the platinum-like compounds of the malonate derivative containing amino or alkylamino 北京市丰硕维康技术开发有限责任公司 2017-04-05 CN disclosed
EP-2759547-B1 PLATINUM COMPOUND HAVING AMINO- OR ALKYLAMINO-CONTAINING SUCCINIC ACID DERIVATIVES AS LEAVING GROUP, PREPARATION METHOD THEREFOR, AND USE THEREOF BEIJING FSWELCOME TECH DEV CO LTD (CN) 2017-01-18 EP disclosed
CN-103649100-B Platinum compound with leaving group of succinic acid derivative containing amino or alkylamino, preparation method and application thereof 北京市丰硕维康技术开发有限责任公司 2016-06-22 CN disclosed
CN-103732601-B The one class treatment platinum compounds of cell proliferation disorders, its preparation method and application 北京市丰硕维康技术开发有限责任公司 2016-06-22 CN disclosed
CN-103703011-B Platinum compounds with leaving group of hydroxy acid derivative containing amino or alkylamino, and preparation method and application thereof 北京市丰硕维康技术开发有限责任公司 2016-06-22 CN disclosed
CN-102993239-A Platinum compound of succinic acid derivative with leaving group containing amino or alkylamino CHEN XIAOPING 2013-03-27 CN disclosed
CN-102863474-A Platinum compounds for treating cell proliferative diseases and preparation method and application thereof CHEN XIAOPING 2013-01-09 CN disclosed
EP-2043611-A2 METAL-CONTAINING FORMULATIONS AND METHODS OF USE Nucryst Pharmaceuticals Corp. (CA) 2009-04-08 EP disclosed
WO-2009014781-A2 METAL-CONTAINING MATERIALS FOR TREATMENT OF BACTERIAL CONDITIONS NUCRYST PHARMACEUTICALS CORP. (CA) 2009-01-29 WO disclosed
US-20080050452-A1 METAL-CONTAINING FORMULATIONS AND METHODS OF USE NUCRYST PHARMACEUTICALS 2008-02-28 US disclosed
US-20080044491-A1 METAL-CONTAINING FORMULATIONS AND METHODS OF USE NUCRYST PHARMACEUTICALS 2008-02-21 US disclosed
US-20080014247-A1 METAL-CONTAINING FORMULATIONS AND METHODS OF USE NUCRYST PHARMACEUTICALS 2008-01-17 US disclosed
US-20080014278-A1 METAL-CONTAINING FORMULATIONS AND METHODS OF USE NUCRYST PHARMACEUTICALS 2008-01-17 US disclosed
WO-2008005705-A2 METAL-CONTAINING FORMULATIONS AND METHODS OF USE NUCRYST PHARMACEUTICALS CORP. (CA) 2008-01-10 WO disclosed